Medical information Clinical review pending

Genetic Testing

Epidermal Growth Factor Receptor Mutation Analysis EGFR Exon 18 19 20 21

This genetic test identifies specific mutations in the EGFR gene (Exons 18, 19, 20, 21) in tumor tissue. It helps guide treatment decisions, particularly for non-small cell lung cancer, by indicating potential eligibility for targeted therapies.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: A sample of tumor tissue (biopsy or surgical resection) is required. Confirm specific sample type and quantity requirements with the laboratory before collection.
Results: Confirm with the laboratory before booking.
Preparation: No specific patient preparation is required. Ensure the tumor tissue sample is properly collected, preserved, and transported according to laboratory guidelines.

Test priceKSh 21,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Epidermal Growth Factor Receptor Mutation Analysis EGFR Exon 18 19 20 21 test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Patients diagnosed with non-small cell lung cancer (NSCLC)
✓Individuals with suspected lung cancer awaiting diagnosis
✓Patients considering targeted therapy for cancer
✓Patients whose cancer has progressed despite initial treatment

In plain language

What this test helps you understand

This test helps identify specific EGFR gene mutations in tumor tissue, which can predict response to certain targeted cancer therapies, particularly tyrosine kinase inhibitors (TKIs). It aids in personalized treatment planning for patients with specific types of cancer, such as non-small cell lung cancer.

The Epidermal Growth Factor Receptor (EGFR) Mutation Analysis (Exons 18, 19, 20, 21) is a genetic test used primarily in the management of certain cancers, especially non-small cell lung cancer (NSCLC). This test looks for specific changes, known as mutations, within the EGFR gene. These mutations can affect how cancer cells grow and respond to different treatments. Identifying these mutations is crucial for selecting the most effective therapy for an individual patient.

This test specifically examines exons 18, 19, 20, and 21 of the EGFR gene. The presence or absence of mutations in these regions can significantly impact treatment strategies. By analyzing a sample of tumor tissue, the test provides valuable information to healthcare providers, enabling them to tailor treatment plans to the specific genetic characteristics of the cancer.

Understanding the results of this test is key to making informed decisions about cancer care. Discussing the findings with your doctor is essential to determine the best course of action based on your individual situation.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo specific patient preparation is required. Ensure the tumor tissue sample is properly collected, preserved, and transported according to laboratory guidelines.

SampleA sample of tumor tissue (biopsy or surgical resection) is required. Confirm specific sample type and quantity requirements with the laboratory before collection.

MethodologySanger Sequencing

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test only analyzes specific exons (18, 19, 20, 21) of the EGFR gene. It may not detect all possible EGFR mutations or mutations in other genes. Results are based on the genetic makeup of the provided tumor sample and may not reflect the entire tumor or potential future changes. A doctor's prescription is required for this test, except in cases of surgery, pregnancy, or travel plans abroad.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

The Epidermal Growth Factor Receptor (EGFR) gene provides instructions for making a protein that helps cells grow, divide, and reproduce. Mutations in this gene can lead to uncontrolled cell growth, contributing to cancer development.

Identifying specific EGFR mutations helps doctors determine if a patient's cancer might respond well to targeted therapies called tyrosine kinase inhibitors (TKIs). This allows for more personalized and potentially effective treatment.

A sample of tumor tissue, typically obtained through a biopsy or surgery, is required for this analysis.

Confirm with the laboratory before booking.

Yes, a doctor's prescription is required for this test, except in cases of surgery, pregnancy, or travel plans abroad.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp